Results from a new prospective clinical trial indicate that high-dose-rate brachytherapy administered in a single, 19 Gray treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer. The study is available online in the International Journal of Radiation Oncology Biology Physics , the flagship journal of the American Society for Radiation Oncology .